The elevated presence of TGF‐β in both tumor cells and their microenvironment, coupled with compelling evidence of its prometastatic role and other different roles such as potentiation of growth, escaping from immune surveillance, and apoptosis, positions it as a promising target for therapy [72]. The gene discussed is TGFB1; the disease is neoplasm.